A multi-country, randomized, double-blind, placebo-controlled study investigating the efficacy and safety of STA363 at two concentrations (60 mg/mL and 120 mg/mL) compared to placebo in patients with chronic discogenic low back pain
Latest Information Update: 23 Feb 2024
At a glance
- Drugs Lactic acid (Primary)
- Indications Back pain
- Focus Therapeutic Use
- Sponsors Stayble Therapeutics
Most Recent Events
- 01 Jan 2024 According to a Stayble Therapeutics Media Release, final results are presented
- 12 Dec 2023 Results presented in the Stayble Therapeutics Media Release.
- 15 Oct 2023 This trial has been completed in Spain, according to European Clinical Trials Database record.